Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molgramostim in pediatric aPAP
NCT06431776Phase 3Recruiting
- Sponsor
- Savara
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Started Oct 2025; status: recruiting.
02
Drugs
molgramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT06431776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431776.